2.59BMarket Cap-5.81P/E (TTM)
15.858High15.150Low1.21MVolume15.420Open15.420Pre Close18.80MTurnover1.95%Turnover RatioLossP/E (Static)169.86MShares34.47052wk High7.33P/B946.74MFloat Cap12.72052wk Low--Dividend TTM62.20MShs Float53.750Historical High--Div YieldTTM4.59%Amplitude3.145Historical Low15.486Avg Price1Lot Size
Immunovant Stock Forum
Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role
Clinical Trial Breakthrough: Immunovant's Batoclimab Shows Remarkable 74% Improvement in MG Patients
Immunovant to host Investor Webcast at 8:00am on Wednesday 03/19/2025
*nfa
Myasthenia Gravis (MG) Phase 3 trial data due by 03/19/2025
*nfa
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$